Efficacy and safety of sildenafil in the treatment of pulmonary arterial hypertension (PAH) after cardiac surgery in Japanese pediatric population - a PAH management- - Sildenafil for pulmonary arterial hypertension after pediatric cardiac surgery

Osaka Medical College0 个研究点目标入组 20 人开始时间: 2015年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients with opened chest Patients with ventricular assist device Patients with extracorporeal membrane oxygenation Patients who are judged as inappropriate to include in this study. Patients with chronic lung disease, retinopathy, or gastrointestinal problems Patients who are received Nitrates or nitric oxide donors in non-intravenous form (oral, sublingual, buccal, transdermal, inhalation or aerosol) within 48 hours prior to receiving study drug treatment or intravenous forms within 2 hours prior to receiving study drug treatment (sildenafil is known to potentiate the hypotensive effects of nitrates; its concurrent use is contraindicated) Patients who are received endothelin antagonists(eg, bosentan) Patients who are received potent cytochrome P450 3A4 inhibitors (eg, erythromycin, ketoconazole, itraconazole, and protease inhibitors) (Use of aprotinin will be allowed; aprotinin does not inhibit cytochrome P450 enzymes) Patients who are received ritonavir or nicorandil.

发起方